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Abstract: Asian countries are striving to transition into innovation-driven economies, and healthcare is a key sector on 
government agendas. Strong funding at academic institutions, high-impact publications, state-of-the-art clinical infra-
structures, vast talent pools, increasing start-up activities and strengthening intellectual property regimes, all aligned 
with coherent government policies, is creating an evolving innovation ecosystem in countries such as China, South Ko-
rea, Singapore, Taiwan and India. Such factors have fuelled a desire from global pharmaceutical companies to seek in-
novation in Asia. In this article, we review the varied strategies of large multinationals using two key aspects—the ca- 
pital investments and operational model—to understand such diverse approaches. Based on a qualitative and quantita-
tive analysis, we have classified these strategies into four distinct approaches—“Captive”, “Partner”, “Service” and 
“Open” models—and discussed case studies that fit into each of these clusters. The model may provide global pharma-
ceutical companies with a framework to evaluate their respective approaches for sourcing innovation and align them 
with the operational, financial, business and strategic needs of their organizations in Asia. 
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1. Introduction 
he United States, Europe and Japan have dom-
inated biomedical innovation over the last sev-
eral decades, with the majority of research and 
development (R&D) funding and the ensuing innova-
tion being localized to these regions[1,2]. However, in 
recent years, the rest of the Asia region, specifically 
China, South Korea, Singapore, Taiwan and India are 
increasingly recognized as key centres of pharma-
ceutical R&D with the potential to deliver future in-
novative drugs[3,4]. 
Unlike the stagnating or declining investments by 
the public and private sectors in the United States and 
Europe, the government and industry investments in 
biomedical research are continuously increasing in 
Asia, most notably in China, Singapore and South 
Korea[1]. The change in biomedical R&D expenditure 
as a percentage of nominal gross domestic product of 
Asian countries like China, South Korea, and Singa-
pore[1] further points to strong innovation focus in the 
bioscience sector. An increasing number of start-up 
companies, high-impact publications, state-of-the-art 
clinical infrastructures, a robust contract research or-
ganization (CRO) industry and vast talent pools[4–6] in 
these countries are fuelling scientific breakthroughs, 
positioning the region as an attractive location to tap 
innovation. 
Asia also presents unique disease and genetics 
landscape for pharmaceutical companies[7]. The region 
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has been at the forefront of clinical studies of diseases 
such as gastric cancer, hepatocellular carcinoma, he-
patitis B and tuberculosis. The advances in persona-
lized medicine that utilize molecular understanding of 
diseases to optimally select and treat patients have 
also resulted in innovative breakthroughs for the Asian 
region, including drugs such as gefitinib and erlotinib 
targeting lung cancer mutations that are much more 
highly prevalent in Asian patients as compared to the 
US or Europe[8]. Such advances provide unique R&D 
strategies for pharmaceutical companies to target spe-
cific diseases in Asia.  
The confluence of these factors has led large mul-
tinationals to focus more R&D efforts in the Asia re-
gion over the past decades. The companies have uti-
lized a range of strategies to tap into this innovation 
landscape, such as internal R&D units, innovation 
centres, virtual research networks, joint ventures and 
open innovation platforms. Such strategies take into 
account the opportunities and challenges of each mar-
ket, the extent of R&D capabilities, language and cul-
tural barriers, and operational alignment with the mul-
tinational pharmaceutical companies’ headquarters. 
In this article, we analyse the various strategies of 
the multinational companies in Asia to understand the 
diverse approaches for accessing biomedical innova-
tion. We utilize data on two key aspects—capital in-
vestments and operational model—to classify such 
strategies into four distinct models being implemented 
by these companies. The capital investments and op-
erating model parameters were defined using a quali-
tative and quantitative approach. For example, a mod-
el that requires in excess of $20 million in investments, 
such as R&D units or innovation centres, is classified 
as a high capital investment. An integrated model 
would be one with significant portions of R&D pur-
sued at internal labs versus a dispersed model where a 
loose network of external alliances is used to push the 
projects toward. Of course, any single model does not 
preclude pursuing an alternate model in parallel—for 
example, an internal lab could also use external colla-
borations—but for simplicity we have classified the 
approaches into clearly defined groups to facilitate a 
comparison between the models. The framework is 
presented in Figure 1 with illustrative cases, and an 
extensive list of examples is included in Table 1. 
2. High Capital, Integrated Operations: “Cap-
tive” model  
Since Roche opened its Shanghai R&D centre in the 
 
 
Figure 1. Framework for models to access biomedical innova-
tion in Asia. The capital investments and operating model were 
used to assign the illustrative cases shown into one of the four 
cells shown in the 2 × 2 matrix. 
 
Zhangjiang Hi-Tech Park in 2004, most of the large 
multinational companies have established an inte-
grated research unit in China[9]. Within Asia, China is 
the preferred location for R&D units with 8 of the top 
10 pharmaceutical companies establishing their R&D 
centres in China, mostly in Beijing or Shanghai. Sin-
gapore is also an attractive destination in Asia[9] al-
though the focus has increasingly been on manufac-
turing of biologics.  
The “Captive” model provides several advantages 
for accessing local innovation. The science unit can 
tap into local talent pool, develop deep local disease 
knowledge, and in parallel, establish research and 
translational networks with academic labs, medical 
centres and CROs. Lilly’s China Research and De-
velopment Center (LCRDC) in Shanghai, which aims 
to discover innovative diabetes medicines with novel 
mechanisms of action that can be tailored specifically 
for the Chinese patients, is one such example. The 
center employs approximately 150 scientists and 
staff[10]. Another example is Johnson & Johnson’s 
Asia-Pacific Innovation Center (J&J IC) in Shanghai, 
China. With science and business experts, the centre 
focuses on building relationships with academia, gov-
ernment and non-profit organizations as well as entre-
preneurs and investors across the Asia Pacific region. 
Having a centralized company culture under such a 
model also allows employees to collaborate internally 
so that complex projects can be advanced rapidly. A 
tight portfolio alignment with global units and IP 
risk-mitigation are added benefits of this model. An 
entrepreneurial culture without multiple decision layers 
typical at headquarters of large companies can further  
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Table 1. Different models for accessing biomedical innovation in Asia 
Description Examples in Asia Pros Cons 
“Captive” model (high capital investment, integrated operation) 
Stand-alone 
in-house R&D 
center 
 AstraZeneca Innovation Centre, China (2007) 
 Biocon’s Syngene and Bristol-Myers Squibb Research 
Centre (BBRC), India (2009) 
 GSK Global R&D Centre, Shanghai, China (2007) 
 Johnson & Johnson’s Asia-Pacific Innovation Center 
(J&J IC), China (2014) 
 Lilly China Research and Development Center in 
Shanghai, China (2012) 
 Merck Beijing R&D center, China (2011) 
 Novartis Institute for Tropical Diseases (NITD), Sin-
gapore (2002) 
 Novartis Institute of BioMedical Research in Shanghai, 
China (2007) 
 Novartis Pharmaceutical Development organization in 
Shanghai, China (2009) 
 Roche R&D Centre in Shanghai, China (2004) 
 Roche’s Pharma Development Center in Shanghai, 
China (2007) 
 Sanofi’s China Clinical Research Unit in Shanghai, 
China (2005) 
 Sanofi’s Biometrics Center in Beijing, China (2008) 
 Pfizer China R&D Center (CRDC) in Shanghai, China  
(2005) 
 Pfizer China R&D Center in Wuhan, China (2010) 
- Tap local talent and disease 
knowledge 
- Ease of collaboration with local 
academic labs, medical centers, 
and CROs 
- Ease of internal collaboration 
- Strategic alignment with global 
portfolio 
- IP risk-mitigation 
- Higher operational cost 
- Potential for sub-optimal 
portfolio prioritization 
- Model not flexible for 
changes 
Acquisition  GlaxoSmithKline’s acquisition of Nanjing MeiRui 
Pharma Co., the China-based pharmaceutical company 
(2010) 
“Partner” model (high capital, dispersed operation) 
Co-development  AZ-Hutchison MediPharma in China (2011) 
 Eli Lilly-Hutchison MediPharma in China (2013) 
 Eli Lilly-Innovent in China (2015) 
 GSK-Hanmi in Korea (2012) 
 Merck-Serono-BeiGene in China (2013) 
- Rapid set-up 
- Access partner asset 
- Control of the work quality 
- Low availability of partners 
with assets in Asia 
- Trust building takes time 
- Potential IP risks  
Joint venture  Pfizer-Hisun Pharmaceutical joint venture in China 
(2012) 
 Samsung Biologics - Biogen Idec joint venture in Ko-
rea (2011) 
“Service” model (low capital, integrated operation) 
Lean resources  AstraZeneca and Wuxi AppTec alliance in China 
(2012) 
 Sanofi and SIBS for China Discovery platform (2008) 
- Cost and risk sharing 
- Usage of existing local in-
fra-structure and capability 
- Flexibility in capacity manage-
ment 
- Potential IP risks  
- Cross-company contamina-
tion of intelligence 
- Management of work quality 
“Open” model (low capital, dispersed operation) 
Open innovation  AstraZeneca’s Open Innovation Portal (2013) 
 AZ–NRPB Drug Repurposing Program in Taiwan (2013) 
 Bayer Grants4Targets (2009), Grant4Leads (2013), 
Grants4Apps (2013) 
 Eli Lilly’s Open Innovation Drug Discovery Program 
(2009) 
- Low cost and low risk 
- Test diverse ideas 
- Organizational and cultural 
changes may be needed 
- IP protection and quality of 
work are hard to control 
- Need strong innovation 
eco-system 
 
provide an ideal innovative environment. However, 
higher operational costs and sub-optimal portfolio 
prioritization are potential risks to be considered and 
mitigated. 
3. High Capital, Dispersed Operations: “Part-
ner” Model 
Such a model of accessing innovation includes, amon- 
gst others, co-development and licensing deals be- 
tween multinational and local companies. One such 
example is AstraZeneca’s global licensing agreement 
with Hutchison MediPharma, for joint development 
and commercialization of Savolitinib, a c-MET re-
ceptor tyrosine kinase inhibitor for the treatment of 
cancer. Another example is Merck-Serono’s licensing, 
co-development and commercialization agreement  
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with BeiGene for a portfolio of cancer molecules. Eli 
Lilly recently announced[11] a partnership with Inno-
vent Biologics in China to co-develop at least three 
experimental cancer drugs including one from Lilly’s 
research labs and two from Innovent. GSK and Han-
mi’s co-development and co-marketing deal[12] for 
evidence-based drug formulation for multiple thera-
peutic areas allows GSK to tap into not only Hanmi’s 
expertise in formulations but also Hanmi’s marketing 
network in Asia, especially in South Korea. In India, 
Sanofi and Eli Lilly partnered with Glenmark on pain 
molecules[13]. Each of the deals above included up-
front payments, and downstream milestones[14] and 
royalties, and is often a mix of either pure in-licensing 
and/or co-development partnerships. 
The “Partner” model provides rapid, flexible access 
to external innovation and has been utilized by many 
of the multinationals in the Asia region. The model 
leverages on the partner’s complementary capabilities 
such as local development knowledge to not only ac-
celerate clinical development in a specific country but 
also secure attractive opportunities for the multina-
tional’s global portfolio. As compared to the “Captive” 
model, this model provides a faster ramp-up and 
access to innovation while still allowing the quality of 
work to be controlled with tight management over-
sight. However, there needs to be a critical mass of 
companies and enough substrate available to imple-
ment such a model, and thus has been most success-
fully used in China, South Korea and India where 
there is increasing venture capital and start-up activi-
ties[3]. In contrast, there have been few such partner-
ships in Taiwan and Singapore, for example, where 
the local ecosystem has not produced a strong pipeline 
of drug candidates. To implement a successful “Part-
ner” model, a pharmaceutical company needs to de-
velop deep networks within the biotech community, 
strong “Partner of Choice” communication and mutual 
trust with local players.  
Joint ventures between the multinational pharma-
ceuticals and a local company are other examples of 
the “Partner” model. Pfizer and Hisun formed a joint 
venture in 2012[15] with USD 250 million invested by 
Pfizer and USD 295 million invested by Hisun respec-
tively to make both branded and low-priced generic 
drugs. It is a mechanism for Pfizer to get better trac-
tion in the China market as well as for Hisun to build 
the capabilities to tap Western markets. Earlier in 2011, 
Merck established a joint venture with Simcere, a 
Chinese company with a track record in drug devel-
opment, to combine resources and expertise for de-
velopment and commercialization of a combined 
portfolio of medicines from both companies in the 
areas of cardiovascular and metabolic diseases. How-
ever, in February 2015, it was announced that Merck 
is pulling out of the joint venture citing the change in 
the market prospects in China, hence highlighting the 
inherent risks of such models in Asia. 
4. Low Capital, Integrated Operations: “Ser-
vice” Model 
The “Service” model is centred around lean resources 
where the bulk of R&D activities are outsourced to 
CROs or are done through collaborative R&D part-
nerships with local companies. This allows the multi-
national pharma to share costs, risks, and deci-
sion-making with the partner company while the ma-
jority of R&D activities are carried out locally using 
the local partner’s existing infrastructures and capabil-
ities. Unlike the above “Captive” and “Partner” mo- 
dels, the “Service” model also allows flexibility for 
the global company to easily adapt to changes in mar-
ket situation and strategy. However, intellectual prop-
erty protection should be carefully devised and a ro-
bust mechanism to monitor and address quality of 
work needs to be put in place. An example is Astra-
Zeneca/MedImmune and WuXi AppTec’s collabo-
ration to develop MEDI5117, a novel antibody for 
rheumatoid arthritis, in China. WuXi brings its capa-
bilities in preclinical and clinical services, as well as 
the capital investment for manufacturing, while As-
traZeneca/MedImmune contributes the molecule and 
technical expertise. Although the partnership is struc-
tured as a joint venture, we have classified this under 
the “Service” model given the focus on a single asset 
and the resource contributions from the partners. The 
Eli Lilly–ChemPartner research collaboration in China 
is another such example as is Sanofi’s strategic part-
nership with Shanghai Institute of Biological Sciences 
(SIBS) as a part of the China Discovery platform in-
volving long-term relationships with top local institu-
tions. 
5. Low Capital, Dispersed Operations: “Open” 
Model 
Open innovation platforms are key examples of this 
model and have been tested by various pharmaceutical 
companies in the Asian region. There are various le-
vels of “openness” with Eli Lilly’s Open Innovation 
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Drug Discovery Program[16] initiated back in 2009 and 
AstraZeneca’s Open Innovation Portal launched in 
2013[17] being completely open, online platforms. In 
contrast, GlaxoSmithKline’s Tres Cantos Open Lab 
Foundation is limited to select partners or diseases of 
interest. For multinationals, these open innovation 
platforms allow the company to spread a vast net 
across diverse set of ideas, thereby diversifying risks 
and testing multiple hypotheses in parallel. These 
open initiatives are also attractive to academia and 
small businesses with novel ideas that can access the 
multinational pharmas’ resources and expertise, and 
collaborate with international pharma scientists to 
progress the science[18]. To implement an “Open” 
model, the multinational companies need to tailor the 
processes and organizational structure for speedy de-
cision making and adopt flexible deal structures. An 
agile and risk-taking culture is also a key for a suc-
cessful “Open” model. There are, however, significant 
hurdles to an “Open” model in Asia. The key aspects 
remain a lack of funding for early-stage projects at 
academic centres, ownership of new intellectual prop-
erty, and sharing on downstream economics. Based on 
our own experience in rolling out AstraZeneca’s 
pharmacology toolbox in Asian countries[17], lack of 
funding seems to be one of the biggest hurdles pre-
venting many investigators in Asia from participating 
in this initiative. An effective way to drive open inno-
vation in Asia is public–private partnerships and one 
such example is the collaboration between AstraZe-
neca and the National Research Program for Bio-
pharmaceuticals (NRPB) in Taiwan. AstraZeneca has 
opened its portfolio of preclinical and clinical mole-
cules for the clinicians and translational researchers in 
Taiwan to explore alternative mechanisms and diseas-
es for the candidate molecules, while NRPB provides 
the funding for the research projects. “Open” models 
work well where an innovation ecosystem is well- 
established, primarily the existence of strong academ-
ic and translational centres that can test novel hypo-
thesis and ideas, such as the example in Taiwan. 
6. Looking Forward 
A key structural change in R&D has been the phar-
maceutical industry’s trend toward externalization 
over the past several years, in part driven by R&D 
productivity and budget pressures[19,20]. More than half 
of recent new drugs have originated from outside of 
the global pharma labs and the focus on accessing the 
best science will continue to push the pharmaceutical 
industry to more active externalization. Although a 
majority of scientific collaborations are still focused 
on the US and Europe biotechs, Asia is a fertile 
ground for future innovation and we have presented 
various models to help access such breakthroughs. 
The models here provide a toolbox for global 
pharmaceutical companies—if capital investments are 
restricted, a “Service” or “Open” model can be used to 
pursue innovation. If capital is not a constraint, a 
“Captive” model might allow the organization to tap 
into the local talent pool and capabilities to pursue 
innovative science. As global companies seek bio-
medical innovation in Asia, it is important to pick the 
appropriate operational model given the resource and 
strategic considerations, and find an ideal partner best 
suited to the company’s objective. However, it is also 
important to consider the overall country’s strength 
and weakness[4], which also explains why an “Open” 
model works better in South Korea and Taiwan, a 
“Partner” model in India, and a “Captive” or “Service” 
model in China. 
However, significant challenges remain. Although 
there have been many new activities in Asia in recent 
years, there has also been reduction or re-distribution 
of efforts in Asia due to various strategic or financial 
reasons. Examples include the dissolution of the 
Merck–Simcere joint venture in China, Lilly’s exit of 
the Singapore Centre for Drug Discovery in 2010, and 
Pfizer’s exit from Singapore in 2013[21–23] with the 
closure of the clinical research centre which had been 
established in 2001. In 2012, Pfizer also exited the 
Asia Research Unit which was established in 2006 in 
Shanghai based on a virtual biotech model aimed to 
“seed, seek, source, and spark” innovation across Asia. 
Tapping Asia’s innovation can also seem daunting 
given language and cultural barriers, paucity of effi-
cient partnering forums, business practices and regula-
tions, and quality of the assets. Finally, alliance man-
agement can pose operational challenges because of 
the need to work across multiple time zones, relative 
inexperience of collaborations between the local and 
multinational partners, and often different expecta-
tions of the outcome. Nevertheless, we believe that 
regardless of the chosen model, local presence with 
knowledge of the R&D landscape, business and cul-
tural aspects is critical for efficient scouting and 
access to the right opportunities in Asia. 
Finally, an interesting aspect is that although many 
multinational companies operate venture investment 
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arms globally, only a few of them, such as Eli Lilly, 
Novartis and J&J seem to be active in Asia. Lilly Asia 
Ventures was established with investment resources of 
USD 100 million in 2008 and invests in companies 
with the potential to grow rapidly as well as those that 
are developing innovative products with potential im-
pact in China and around the world. As per publicly 
disclosed information, Lilly Asia Ventures is currently 
managing 16 portfolio[24] companies and investments 
in the life sciences and healthcare sectors, with several 
portfolio companies in Asia. Novartis Korea Venture 
Fund, also established in 2008, planned to invest for 
novel therapeutics and platforms with a focus on dis-
eases prevalent in Asia and, as per public information, 
it is currently managing three portfolio[25] companies 
in Korea. Furthermore an increasing trend, at least in 
countries like China, is local venture capital funds 
seeking earlier stage investments, in contrast to the 
trend in established markets such as Europe and the 
United States, positioning Asia as an important ground 
for investing in new innovative start-ups. 
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